GuidelineMemorias do Instituto Oswaldo Cruz2014
Drug discovery for Chagas disease should consider Trypanosoma cruzi strain diversity.
Guideline in Memorias do Instituto Oswaldo Cruz, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Orally transmitted Chagas disease outbreaks in Latin America: a comprehensive systematic review and public health implications.Frontiers in public health · 2026Pooled it
- In vitro susceptibility of Trypanosoma cruzi discrete typing units (DTUs) to benznidazole: A systematic review and meta-analysis.PLoS neglected tropical diseases · 2021Pooled it
- Pooled it
- Population pharmacokinetic-pharmacodynamic analysis of benznidazole monotherapy and combination therapy with fosravuconazole in chronic Chagas disease (BENDITA).PLoS neglected tropical diseases · 2025Trial
- Genetic polymorphism of Trypanosoma cruzi bloodstream populations in adult chronic indeterminate Chagas disease patients from the E1224 clinical trial.The Journal of antimicrobial chemotherapy · 2022Trial
- Trial
- Epitope mapping of vaccine antigens Tc24 and TSA1 with antibodies from Trypanosoma cruzi-infected patients.Genes and immunity · 2026Article
- Discovery and Early Optimization of 1Journal of medicinal chemistry · 2025Article
- Albaconazole Polymeric Nanocapsules for TreatingPathogens (Basel, Switzerland) · 2025Article
- Exploring Binding Sites in Chagas Disease Protein TcP21 Using Integrated Mixed Solvent Molecular Dynamics Approaches.Journal of chemical information and modeling · 2025Article
- Screening of synthetic 1,2,3-triazolic compounds inspired by SRPIN340 as anti-Trypanosoma cruzi agents.Revista da Sociedade Brasileira de Medicina Tropical · 2024Article
- Fifteen Years after the Definition ofLife (Basel, Switzerland) · 2023Review
- Lupeol Acetate and α-Amyrin Terpenes Activity againstTropical medicine and infectious disease · 2023Article
- Impact of Laboratory-Adapted IntracellularMicroorganisms · 2023Article
- Lipase-Catalyzed Synthesis and Biological Evaluation ofACS medicinal chemistry letters · 2023Article
- State-of-the-Art in the Drug Discovery Pathway for Chagas Disease: A Framework for Drug Development and Target Validation.Research and reports in tropical medicine · 2023Review
- Genomic surveillance: a potential shortcut for effective Chagas disease management.Memorias do Instituto Oswaldo Cruz · 2023Article
- Chagas Heart Disease: Beyond a Single Complication, from Asymptomatic Disease to Heart Failure.Journal of clinical medicine · 2022Review
- Molecular Characterization of Four Mexican Isolates of Trypanosoma cruzi and Their Profile Susceptibility to Nifurtimox.Acta parasitologica · 2022Article
- Phenotypic Evaluation of Nucleoside Analogues againstMolecules (Basel, Switzerland) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This opinion piece presents an approach to standardisation of an important aspect of Chagas disease drug discovery and development: selecting Trypanosoma cruzi strains for in vitro screening. We discuss the rationale for strain selection representing T. cruzi diversity and provide recommendations on the preferred parasite stage for drug discovery, T. cruzi discrete typing units to include in the panel of strains and the number of strains/clones for primary screens and lead compounds. We also consider experimental approaches for in vitro drug assays. The Figure illustrates the current Chagas disease drug-discovery and development landscape.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.